The scientist’s investigation covers issues in Internal medicine, Respiratory disease, Pathology, Cell biology and Anesthesia. His studies in Internal medicine integrate themes in fields like Gastroenterology, Endocrinology and Surgery. His research integrates issues of Pneumocystis carinii, Pneumonia and Radiology, Pulmonary hypertension, Pulmonary function testing in his study of Respiratory disease.
His Pathology research integrates issues from Central nervous system disease, Neuroscience and Lissencephaly. Jeffrey A. Golden has included themes like Apoptosis, Anatomy, Bone morphogenetic protein and Bone morphogenetic protein 2 in his Cell biology study. Jeffrey A. Golden has researched Anesthesia in several fields, including Bronchoalveolar lavage and Brain damage.
His primary scientific interests are in Internal medicine, Lung, Pathology, Lung transplantation and Neuroscience. His work deals with themes such as Gastroenterology, Endocrinology and Surgery, which intersect with Internal medicine. The various areas that Jeffrey A. Golden examines in his Lung study include Radiology and Immunology.
Jeffrey A. Golden studies Pathology, focusing on Pathogenesis in particular. Jeffrey A. Golden frequently studies issues relating to Cell migration and Neuroscience. His Bronchoalveolar lavage study integrates concerns from other disciplines, such as Pharmacokinetics and Pneumocystis carinii.
Jeffrey A. Golden mostly deals with Internal medicine, Lung, Lung transplantation, Immunology and Idiopathic pulmonary fibrosis. His Internal medicine research includes themes of Gastroenterology, Oncology and Histopathology. His study in Lung is interdisciplinary in nature, drawing from both Biomarker, Transcriptome, Immune system and Pathology.
His work in Pathology addresses subjects such as Gene expression, which are connected to disciplines such as Allograft rejection and Downregulation and upregulation. His Lung transplantation study combines topics in areas such as Prospective cohort study, Quality of life, Lung injury and Hazard ratio. His work investigates the relationship between Idiopathic pulmonary fibrosis and topics such as FEV1/FVC ratio that intersect with problems in Exacerbation, Randomized controlled trial and Tolerability.
His primary areas of investigation include Internal medicine, Lung transplantation, Prospective cohort study, Idiopathic pulmonary fibrosis and Lung. His Internal medicine study frequently draws connections between related disciplines such as Oncology. The study incorporates disciplines such as Adoptive cell transfer, Lung injury and Endogeny in addition to Lung transplantation.
His Prospective cohort study research is multidisciplinary, incorporating perspectives in Proportional hazards model and Interstitial lung disease. As a part of the same scientific family, Jeffrey A. Golden mostly works in the field of Idiopathic pulmonary fibrosis, focusing on FEV1/FVC ratio and, on occasion, Exacerbation, Tolerability and Randomized controlled trial. The Lung study which covers Cellular Ageing that intersects with Immunology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
The combined functions of proapoptotic Bcl-2 family members bak and bax are essential for normal development of multiple tissues.
Tullia Lindsten;Andrea J. Ross;Ayala King;Wei Xing Zong.
Molecular Cell (2000)
Cyclophosphamide versus placebo in scleroderma lung disease.
Donald P. Tashkin;Robert Elashoff;Philip J. Clements;Jonathan Goldin.
The New England Journal of Medicine (2006)
Semaphorin III is needed for normal patterning and growth of nerves, bones and heart
Oded Behar;Jeffrey A. Golden;Hiroshi Mashimo;Frederick J. Schoen.
Bronchoalveolar Lavage and Transbronchial Biopsy for the Diagnosis of Pulmonary Infections in the Acquired Immunodeficiency Syndrome
C Broaddus;M D Dake;M S Stulbarg;W Blumenfeld.
Annals of Internal Medicine (1985)
Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial
Donald P. Tashkin;Michael D. Roth;Philip J. Clements;Daniel E. Furst.
The Lancet Respiratory Medicine (2016)
Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease.
Donald P. Tashkin;Robert Elashoff;Philip J. Clements;Michael D. Roth.
American Journal of Respiratory and Critical Care Medicine (2007)
Intrapulmonary Pharmacokinetics of Linezolid
John E. Conte;Jeffrey A. Golden;Juliana Kipps;Elisabeth Zurlinden.
Antimicrobial Agents and Chemotherapy (2002)
Noninvasive evaluation of pulmonary artery pressure during exercise by saline-enhanced Doppler echocardiography in chronic pulmonary disease.
R B Himelman;M Stulbarg;B Kircher;E Lee.
High-resolution CT diagnosis of emphysema in symptomatic patients with normal chest radiographs and isolated low diffusing capacity.
J S Klein;G Gamsu;W R Webb;J A Golden.
Bronchial hyperirritability in healthy subjects after exposure to ozone
J A Golden;J A Nadel;H A Boushey.
The American review of respiratory disease (2015)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: